MYCN has been demonstrated to have lower methylation levels in relapsed children with B-cell acute lymphoblastic leukemia (B-ALL), which was consistent with the usage of MYCN in this study as a key feature to differentiate B-ALL (68). This evidence concerns the gene MYCN and acute lymphoblastic leukemia.